Suzhou Union Biopharm Biosciences

Suzhou Union Biopharm Biosciences is a wholly-owned subsidiary of Shanghai Junshi Biosciences, serving as a primary manufacturing and R&D hub for the group's innovative biopharmaceutical portfolio. Established in 2013, the company operates a state-of-the-art production facility in Suzhou Wujiang that has successfully passed inspections by the NMPA, FDA, and EMA. The company is responsible for the pilot and commercial-scale production of key assets, including the PD-1 inhibitor toripalimab (TUOYI) and the PCSK9 inhibitor ongericimab (JUNSHIDA). Suzhou Union Biopharm Biosciences plays a pivotal role in Junshi's global expansion, providing high-quality manufacturing capabilities for monoclonal antibodies, bispecific antibodies, and recombinant proteins. The site also supports the development of biosimilars and vaccines for oncology, autoimmune, and infectious diseases.